ThemenmitKopf (@topicswithhead) sur getquin

Financial performance:

Revenue: Total revenue for the first nine months of 2024 amounted to DKK 15.085 million, an increase of 29% compared to DKK 11.715 million in the same period in 2023.
Net profit: Net profit for the first nine months of 2024 amounted to DKK 3.999 million, compared to DKK 3.649 million in the same period last year.

Balance sheet overview:

Total assets: As of September 30, 2024, total assets amounted to DKK 39.660 million, an increase against DKK 35.335 million as of December 31, 2023.
Equity: Equity at September 30, 2024 was DKK 31.922 million, compared to DKK 31.656 million at December 31, 2023.

Profit and loss account:

Operating result: Operating profit for the first nine months of 2024 amounted to DKK 4,543 million, compared with DKK 3,570 million in the prior-year period.
Operating expenses: Operating expenses amounted to DKK 10.542 million compared to DKK 8.145 million in the same period in 2023.

Cash flow overview:

Operating activities: Net cash flow from operating activities amounted to DKK 5,059 million for the first nine months of 2024, compared with DKK 5,708 million in the same period in 2023.
Investing activities: Net cash flow for investing activities amounted to DKK -9.989 million, primarily due to the acquisition of ProfoundBio.
Financing activities: Net cash flow for financing activities amounted to DKK -3.922 million, primarily due to the repurchase of own shares.

Key ratios and profitability metrics:

Equity ratio: Equity ratio decreased to 80% at September 30, 2024, compared to 90% at December 31, 2023.
Earnings per share: Basic earnings per share for the first nine months of 2024 amounted to DKK 62.09, compared with DKK 55.88 in the prior-year period.

Competitive position:

Genmab has entered into over 20 strategic partnerships with companies in the biotechnology and pharmaceutical industries.

Forecasts and management commentary:

Revenue forecast: Revenue guidance for 2024 updated to DKK 21.1 - 21.7 billion, reflecting growth of 30% YoY.
Operating profit: Operating profit forecast raised to DKK 6.2 - 7.1 billion (excluding acquisition and integration costs).

Risks and opportunities:

Risks: A lawsuit filed by Chugai in Japan against Genmab and AbbVie for alleged patent infringement in connection with EPKINLY.
Opportunities: Expansion of the product pipeline and further development of own clinical products.

Summary of results:

Positive aspects:

Sales growth: Sales increase of 29%.
Net profit increase: Net profit increased to DKK 3,999 million.
Strategic acquisitions: Acquisition of ProfoundBio to strengthen the product pipeline.
Improved forecast: Adjusted revenue and operating profit forecast.
Strong partnerships: More than 20 strategic partnerships.

Negative aspects:

Decrease in cash flow: Decrease in cash generated from operating activities.
Rising liabilities: Increased level of debt.
Decrease in equity ratio: Decrease in equity ratio from 90% to 80%.
Patent lawsuit: Ongoing patent lawsuit in Japan.
High acquisition costs: High capital outflow due to the acquisition of ProfoundBio.